Pharma Stocks Show a Positive Trend
The upward trend in the pharmaceutical sector for the week ending July 17, 2015, was not caused by the oversold or overbought condition.
What Are Penny Stocks, and Can They Make You Money?
Newcomers to the stock market often dream of fast profits but don’t have large investing accounts. Then they hear about this thing called “penny stocks.”
Analysts Give Positive Recommendations to MannKind in March
Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March 26.
MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
On December 13, 2018, Akebia Therapeutics issued a press release announcing the completion of its merger with Keryx Biopharmaceuticals.
What Analysts Are Recommending for MannKind and Akebia in March
On March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price.
United Therapeutics Enters into a Collaboration with MannKind
United Therapeutics (UTHR) and MannKind Corp. entered into a global agreement to develop and commercialize a pulmonary hypertension product.
How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
IBB Returns to Positive: How Did Its Holdings Perform?
The iShares NASDAQ Biotechnology ETF followed the market trend and gained 1.1% after a five-day losing streak, a positive beginning for the month of May.
XBI Tops Biotech ETF’s for the Week Ended November 27
Sarepta Therapeutics closed at $37.4 and was trading 15.2% above the 100-day moving average price of $32.5. It has a weight of 0.8% in XBI.